Material Type
Poster
Axicabtagene Ciloleucel Manufacturing Experience From Launch to Present Day: a United States Perspective
Author: Alquist, L
Yescarta
Poster
Real time, point-of-need measurement of Blood CD19 CAR-T vector load is concordant with standard ddPCR method
Author: Bharadwaj, S
Yescarta
Poster
Impact of Complete Response on Long-Term Survival Among Patients Receiving Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma
Author: Ghobadi, A
Yescarta
Poster
Minority Patients Receiving CAR T-Cell Therapy in the United States Between 2020-2025: A SEER-Based Projection on Racial Composition and Impact of Proximity to Authorized Treatment Centers
Author: Goldfinger, M
Yescarta, Tecartus
Poster
An Updated Comparison of Overall Survival with Brexucabtagene Autoleucel (Brexu-cel) CAR T-Cell Therapy (ZUMA-2) Versus Standard of Care (SCHOLAR-2) in Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor (BTKi)
Author: Hess, G
Tecartus
Poster
A cost-effectiveness analysis of axicabtagene ciloleucel versus epcoritamab in third-line diffuse large B-cell lymphoma patients in the United States
Author: Locke, F
Yescarta
Poster
A cost-effectiveness analysis of axicabtagene ciloleucel versus glofitamab in third-line diffuse large B-cell lymphoma patients in the United States
Author: Locke, F
Yescarta
Poster
Contemporary Treatment Options Beyond Chimeric Antigen Receptor T-Cell Therapies for Patients With Relapsed or Refractory Large B-Cell Lymphoma: A Systematic Literature Review
Author: Lunning, M
Yescarta
Poster
Medicare Utilization and Cost Trends for CAR T Cell Therapies in the Treatment of Large B-Cell Lymphoma
Author: Wu, J
Yescarta